Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis

References

• van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084–2098.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617–628.
   PubMed Web of Science ®Google Scholar
• Ingre C, Roos PM, Piehl F, et al. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181–193.
   PubMed Web of Science ®Google Scholar
• Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93(11):1617–1628.
   PubMed Web of Science ®Google Scholar
• Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17–23.
   PubMed Web of Science ®Google Scholar
• Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Edaravone: a new drug approved for ALS. Cell. 2017;171(4):725.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012(3):CD001447.
   PubMedGoogle Scholar
• Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17(5):385–386.
   PubMed Web of Science ®Google Scholar
• Jami MS, Salehi-Najafabadi Z, Ahmadinejad F, et al. Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochem Int. 2015;90:134–141.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Nishimura Y, Shiide Y, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188–1197.
   PubMed Web of Science ®Google Scholar
• Petrov D, Mansfield C, Moussy A, et al. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.
   PubMed Web of Science ®Google Scholar
• Bahrami F, Pourgholami MH, Mekkawy AH, et al. Monepantel induces autophagy in human ovarian cancer cells through disruption of the mTOR/p70S6K signalling pathway. Am J Cancer Res. 2014;4(5):558–571.
   PubMed Web of Science ®Google Scholar
• Querfurth H, Lee HK. Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol Neurodegener. 2021;16(1):44.
   PubMed Web of Science ®Google Scholar
• Benavides-Serrato A, Saunders JT, Holmes B, et al. Repurposing potential of riluzole as an ITAF inhibitor in mTOR therapy resistant glioblastoma. Int J Mol Sci. 2020;21(1):344.
   PubMed Web of Science ®Google Scholar
• Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014;19(3):373–379.
   PubMed Web of Science ®Google Scholar
• Bos PH, Lowry ER, Costa J, et al. Development of MAP4 kinase inhibitors as motor neuron-protecting agents. Cell Chem Biol. 2019;26(12):1703–1715 e37.
   PubMed Web of Science ®Google Scholar
• Smith HL, Mallucci GR. The unfolded protein response: mechanisms and therapy of neurodegeneration. Brain. 2016;139(Pt 8):2113–2121.
   PubMedGoogle Scholar
• Wong YL, LeBon L, Basso AM, et al. eIF2B activator prevents neurological defects caused by a chronic integrated stress response. Elife. 2019;8:e42940.
   PubMed Web of Science ®Google Scholar
• GlobeNewswire [Internet]. California (South San Francisco): denali Therapeutics; [cited 2022 Sept 30]. Available from: https://www.globenewswire.com/news-release/2021/09/09/2294411/0/en/Denali-Therapeutics-Announces-Initiation-of-Phase-1b-Study-of-EIF2B-Activator-DNL343-in-ALS.html
   Google Scholar
• Wen J, Li S, Zheng C, et al. Tetramethylpyrazine nitrone improves motor dysfunction and pathological manifestations by activating the PGC-1alpha/Nrf2/HO-1 pathway in ALS mice. Neuropharmacology. 2021;182:108380.
   PubMed Web of Science ®Google Scholar
• Huang C, Li J, Zhang G, et al. TBN improves motor function and prolongs survival in a TDP-43M337V mouse model of ALS. Hum Mol Genet. 2021;30(16):1484–1496.
   PubMed Web of Science ®Google Scholar
• Liu C, Arnold R, Henriques G, et al. Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in progeria cells. Cells. 2019;8(10):1276.
   PubMed Web of Science ®Google Scholar
• Shan G, Li Y, Zhang J, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol. 2008;26(8):933–940.
   PubMed Web of Science ®Google Scholar
• Emde A, Eitan C, Liou LL, et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. 2015;34(21):2633–2651.
   PubMed Web of Science ®Google Scholar
• Felicetti T, Cecchetti V, Manfroni G. Modulating microRNA processing: enoxacin, the progenitor of a new class of drugs. J Med Chem. 2020;63(21):12275–12289.
   PubMed Web of Science ®Google Scholar
• ema.europa.eu [Internet]. Amsterdam: European Medicines Agency; [cited 2022 Oct 31]. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151459
   Google Scholar
• Wright CJ, McCormack PL. Trametinib: first global approval. Drugs. 2013;73(11):1245–1254.
   PubMed Web of Science ®Google Scholar
• Palomo V, Nozal V, Rojas-Prats E, et al. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br J Pharmacol. 2021;178(6):1316–1335.
   PubMed Web of Science ®Google Scholar
• Sahana TG. Mitogen-Activated Protein ZK, Kinase pathway in amyotrophic lateral sclerosis. Biomedicines. 2021;9(8):696.
   PubMed Web of Science ®Google Scholar
• Shi Y, Lin S, Staats KA, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313–325.
   PubMed Web of Science ®Google Scholar
• Imamura K, Izumi Y, Watanabe A, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(391):eaaf3962.
   PubMed Web of Science ®Google Scholar
• Imamura K, Izumi Y, Nagai M, et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): a multicentre, open-label, dose-escalation phase 1 trial. eClinicalMedicine. 2022;53:101707. cited 2022 Nov 5.
   PubMedGoogle Scholar
• Han J, Chitu V, Stanley ER. Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges. Cell Mol Life Sci. 2022;79(4):219.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhou D, Guo J, et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2006;46(9):421–428.
   PubMed Web of Science ®Google Scholar
• Takata M, Tanaka H, Kimura M, et al. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170(2):341–351.
   PubMed Web of Science ®Google Scholar
• Lingor P, Weber M, Camu W, et al. ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase iia trial of safety, tolerability and efficacy of the Rho Kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis. Front Neurol. 2019;10:293.
   PubMed Web of Science ®Google Scholar
• Mifflin L, Hu Z, Dufort C, et al. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2021;118(13):e2025102118.
   PubMed Web of Science ®Google Scholar
• ALS NewsToday [Internet]. Florida: bioNews, Inc.; [cited 2022 Oct 30]. Available from: https://alsnewstoday.com/news/patient-dosing-starts-phase-2-trial-oral-sar443820-als/
   Google Scholar
• NeuroSence [Internet]. Cambridge: neuroSence Therapeutics; [cited 2022 Jun 28]. Available from: https://www.neurosense-tx.com/primec/
   Google Scholar
• Salomon-Zimri S, Pushett A, Russek-Blum N, et al. Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2022;1–9. DOI:10.1080/21678421.2022.2119868
   PubMed Web of Science ®Google Scholar
• De Nicola AF, Meyer M, Guennoun R, et al. Insights into the therapeutic potential of glucocorticoid receptor modulators for neurodegenerative diseases. Int J Mol Sci. 2020;21(6):2137.
   PubMed Web of Science ®Google Scholar
• Moser JM, Bigini P, Schmitt-John T. The wobbler mouse, an ALS animal model. Mol Genet Genomics. 2013;288(5–6):207–229.
   PubMed Web of Science ®Google Scholar
• Meyer M, Kruse MS, Garay L, et al. Long-term effects of the glucocorticoid receptor modulator CORT113176 in murine motoneuron degeneration. Brain Res. 2020;1727:146551.
   PubMed Web of Science ®Google Scholar
• Kallstig E, McCabe BD, Schneider BL. The Links between ALS and NF-kappaB. Int J Mol Sci. 2021;22(8):3875.
   PubMed Web of Science ®Google Scholar
• Dutta K, Patel P, Julien JP. Protective effects of Withania somnifera extract in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2018;309:193–204.
   PubMed Web of Science ®Google Scholar
• Dutta K, Patel P, Rahimian R, et al. Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration. Neurotherapeutics. 2017;14(2):447–462.
   PubMed Web of Science ®Google Scholar
• Kumar S, Phaneuf D, Julien JP. Withaferin-A treatment alleviates TAR DNA-binding protein-43 pathology and improves cognitive function in a mouse model of FTLD. Neurotherapeutics. 2021;18(1):286–296.
   PubMed Web of Science ®Google Scholar
• Ovadia E, inventor; Immunity Pharma Ltd, assignee. Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS). United States patent US 2021/0100869 A1. 2020 Nov 6.
   Google Scholar
• ALS NewsToday [Internet]. Florida: bioNews, Inc.; [cited 2022 Oct 31]. Available from: https://alsnewstoday.com/news/investigational-treatment-ipl344-safely-slows-als-progression-in-small-phase-1-2a-trial/
   Google Scholar
• Chen Y, Podojil JR, Kunjamma RB, et al. Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis. Brain. 2019;142(2):344–361.
   PubMedGoogle Scholar
• Das I, Krzyzosiak A, Schneider K, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348(6231):239–242.
   PubMed Web of Science ®Google Scholar
• Carrara M, Sigurdardottir A, Bertolotti A. Decoding the selectivity of eIF2alpha holophosphatases and PPP1R15A inhibitors. Nat Struct Mol Biol. 2017;24(9):708–716.
   PubMed Web of Science ®Google Scholar
• ALS NewsToday [Internet]. Florida: bioNews, Inc.; [cited 2022 Oct 29]. Available from: https://alsnewstoday.com/news/inflectis-okd-to-start-phase-2-trial-of-ifb-088-for-bulbar-onset-als/
   Google Scholar
• Crippa V, D’Agostino VG, Cristofani R, et al. Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep. 2016;6(1):22827.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Crippa V, Cereda C, et al. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open. 2019;9(5):e028486.
   PubMedGoogle Scholar
• Dunlop RA, Carney JM. Mechanisms of L-Serine-Mediated Neuroprotection Include Selective Activation of Lysosomal Cathepsins B and L. Neurotox Res. 2021;39(1):17–26.
   PubMed Web of Science ®Google Scholar
• Davis DA, Cox PA, Banack SA, et al. l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND. J Neuropathol Exp Neurol. 2020;79(4):393–406.
   PubMed Web of Science ®Google Scholar
• Levine TD, Miller RG, Bradley WG, et al. Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1–2):107–111.
   PubMed Web of Science ®Google Scholar
• Posa D, Martinez-Gonzalez L, Bartolome F, et al. Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. Mol Neurobiol. 2019;56(4):2424–2432.
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez L, Gonzalo-Consuegra C, Gomez-Almeria M, et al. Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3beta as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2021;22(16):8975.
   PubMed Web of Science ®Google Scholar
• Martinez NW, Gomez FE, Matus S. The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration. Front Aging Neurosci. 2021;13:638208.
   PubMed Web of Science ®Google Scholar
• Zu T, Guo S, Bardhi O, et al. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci U S A. 2020;117(31):18591–18599.
   PubMed Web of Science ®Google Scholar
• Kaneb HM, Sharp PS, Rahmani-Kondori N, et al. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One. 2011;6(9):e24189.
   PubMed Web of Science ®Google Scholar
• Tsang CK, Qi H, Liu LF, et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007;12(3–4):112–124.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li L, Chen S, et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7(4):412–425.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Majumder S, Deng JJ, et al. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem. 2009;284(40):27416–27424.
   PubMed Web of Science ®Google Scholar
• Cheng CW, Lin MJ, Shen CK. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP. J Neurogenet. 2015;29(2–3):59–68.
   PubMed Web of Science ®Google Scholar
• Chennampally P, Sayed-Zahid A, Soundararajan P, et al. A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin. Sci Rep. 2021;11(1):18168.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, D’Amico R, Zucchi E, et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore). 2018;97(24):e11119.
   PubMed Web of Science ®Google Scholar
• Cunha-Oliveira T, Montezinho L, Mendes C, et al. Oxidative Stress in Amyotrophic Lateral Sclerosis: pathophysiology and Opportunities for Pharmacological Intervention. Oxid Med Cell Longev. 2020;2020:5021694.
   PubMed Web of Science ®Google Scholar
• Shichiri M. The role of lipid peroxidation in neurological disorders. J Clin Biochem Nutr. 2014;54(3):151–160.
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Heerinckx F, De Jager R, et al. Randomized, clinical trial of RT001: early signals of efficacy in Friedreich’s ataxia. Mov Disord. 2018;33(6):1000–1005.
   PubMed Web of Science ®Google Scholar
• Adams D, Midei M, Dastgir J, et al. Treatment of infantile neuroaxonal dystrophy with RT001: a di-deuterated ethyl ester of linoleic acid: report of two cases. JIMD Rep. 2020;54(1):54–60.
   PubMedGoogle Scholar
• Yerton M, Winter A, Kostov A, et al. An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor. Muscle Nerve. 2022;66(4):421–425.
   PubMed Web of Science ®Google Scholar
• Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580–588.
   PubMed Web of Science ®Google Scholar
• Scaricamazza S, Salvatori I, Amadio S, et al. Repurposing of Trimetazidine for amyotrophic lateral sclerosis: a study in SOD1(G93A) mice. Br J Pharmacol. 2022;179(8):1732–1752.
   PubMed Web of Science ®Google Scholar
• de la Rubia JE, Drehmer E, Platero JL, et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1–2):115–122.
   PubMed Web of Science ®Google Scholar
• Bedlack R, Group AL. ALSUntangled 44: curcumin. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7–8):623–629.
   PubMed Web of Science ®Google Scholar
• Chico L, Ienco EC, Bisordi C, et al. Amyotrophic Lateral Sclerosis and Oxidative Stress: a Double-Blind Therapeutic Trial After Curcumin Supplementation. CNS Neurol Disord Drug Targets. 2018;17(10):767–779.
   PubMed Web of Science ®Google Scholar
• Dost FS, Kaya D, Ontan MS, et al. Theracurmin Supplementation May be a Therapeutic Option for Older Patients with Alzheimer’s Disease: a 6-Month Retrospective Follow-Up Study. Curr Alzheimer Res. 2021;18(14):1087–1092.
   PubMed Web of Science ®Google Scholar
• Meira Martins LA, Vieira MQ, Ilha M, et al. The interplay between apoptosis, mitophagy and mitochondrial biogenesis induced by resveratrol can determine activated hepatic stellate cells death or survival. Cell Biochem Biophys. 2015;71(2):657–672.
   PubMed Web of Science ®Google Scholar
• Madruga E, Maestro I, Mitophagy Modulation MA. a New Player in the Race against ALS. Int J Mol Sci. 2021;22(2):740.
   PubMed Web of Science ®Google Scholar
• Albani D, Polito L, Signorini A, et al. Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors. 2010;36(5):370–376.
   PubMed Web of Science ®Google Scholar
• Mancuso R, Del Valle J, Modol L, et al. Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics. 2014;11(2):419–432.
   PubMed Web of Science ®Google Scholar
• Proano B, Casani-Cubel J, Benlloch M, et al. Is dutasteride a therapeutic alternative for amyotrophic lateral sclerosis? Biomedicines. 2022;10(9):2084.
   PubMed Web of Science ®Google Scholar
• Mori A, Cross B, Uchida S, et al. How are Adenosine and Adenosine A2A receptors involved in the pathophysiology of amyotrophic lateral sclerosis? Biomedicines. 2021;9(8):1027.
   PubMed Web of Science ®Google Scholar
• Sebastiao AM, Rei N, Ribeiro JA. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Front Pharmacol. 2018;9:267.
   PubMed Web of Science ®Google Scholar
• Ng SK, Higashimori H, Tolman M, et al. Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2015;267:115–122.
   PubMed Web of Science ®Google Scholar
• Gibson LC, Hastings SF, McPhee I, et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol. 2006;538(1–3):39–42.
   PubMed Web of Science ®Google Scholar
• Schwenkgrub J, Zaremba M, Mirowska-Guzel D, et al. Ibudilast: a nonselective phosphodiesterase inhibitor in brain disorders. Postepy Hig Med Dosw Online. 2017;71137–148.
   Web of Science ®Google Scholar
• Babu S, Hightower BG, Chan J, et al. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. Neuroimage Clin. 2021;30:102672.
   PubMed Web of Science ®Google Scholar
• Matsuda K, Iwaki Y, Makhay M, et al. Interaction (nonuniformity) of ALS progression and the efficacy of MN-166 (ibudilast). Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1):262–288.
   PubMedGoogle Scholar
• Oskarsson B, Maragakis N, Bedlack RS, et al. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegener Dis Manag. 2021;11(6):431–443.
   PubMed Web of Science ®Google Scholar
• Huang X, El-Sayed IH, Yi X, et al. Gold nanoparticles: catalyst for the oxidation of NADH to NAD(+). J Photochem Photobiol B. 2005;81(2):76–83.
   PubMed Web of Science ®Google Scholar
• Vucic S, Kiernan MC, Menon P, et al. Study protocol of RESCUE-ALS: a Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open. 2021;11(1):e041479.
   PubMed Web of Science ®Google Scholar
• ALS NewsToday [Internet]. Florida: bioNews, Inc.; [cited 2022 Nov 3]. Available from: https://alsnewstoday.com/news/early-cnm-au8-treatment-als-continues-show-survival-benefits/
   Google Scholar
• Joo IS, Hwang DH, Seok JI, et al. Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Clin Neurol. 2007;3(4):181–186.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Pinto S, Costa J, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(5):456–460.
   PubMed Web of Science ®Google Scholar
• Westergard T, McAvoy K, Russell K, et al. Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. EMBO Mol Med. 2019;11(2):e9423.
   PubMed Web of Science ®Google Scholar
• Wong C, Dakin RS, Williamson J, et al. Motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open. 2022;12(7):e064173.
   PubMedGoogle Scholar
• Wang L, Li C, Chen X, et al. Abnormal serum iron-status indicator changes in Amyotrophic Lateral Sclerosis (ALS) patients: a meta-analysis. Front Neurol. 2020;11:380.
   PubMed Web of Science ®Google Scholar
• Moreau C, Danel V, Devedjian JC, et al. Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal. 2018;29(8):742–748.
   PubMed Web of Science ®Google Scholar
• Hider RC, Hoffbrand AV, Longo DL. The role of deferiprone in iron chelation. N Engl J Med. 2018;379(22):2140–2150.
   PubMed Web of Science ®Google Scholar
• Soon CPW, Donnelly PS, Turner BJ, et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 2011;286(51):44035–44044.
   PubMed Web of Science ®Google Scholar
• Kuo MTH, Beckman JS, Shaw CA. Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model. Neurobiol Dis. 2019;130:104495.
   PubMed Web of Science ®Google Scholar
• als-mnd.org [Internet]. Glasgow: international Alliance of ALS/MND Associations; [cited 2022 Nov 5]. Available from: https://www.als-mnd.org/support-for-pals-cals/drugs-in-development/cmd-cuatsm/
   Google Scholar
• Couly S, Khalil B, Viguier V, et al. Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis. Hum Mol Genet. 2020;29(4):529–540.
   PubMed Web of Science ®Google Scholar
• Estevez-Silva HM, Mediavilla T, Giacobbo BL, et al. Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2022;55(5):1356–1372.
   PubMed Web of Science ®Google Scholar
• Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model. Cell Death Dis. 2019;10(3):210.
   PubMedGoogle Scholar
• ALS NewsToday [Internet]. Florida: bioNews, Inc.; [cited 2022 Nov 4]. Available from: https://alsnewstoday.com/news/pridopidine-fda-orphan-drug-designation-als-treatment/
   Google Scholar
• Asla MM, Nawar AA, Abdelsalam A, et al. The efficacy and safety of pridopidine on treatment of patients with huntington’s disease: a systematic review and meta-analysis. Mov Disord Clin Pract. 2022;9(1):20–30.
   PubMed Web of Science ®Google Scholar
• ALS NewsToday [Internet]. Florida: bioNews, Inc.; [cited 2022 Oct 28]. Available from: https://alsnewstoday.com/news/als-therapy-verdiperstat-fails-healey-trial-efficacy-goals/
   Google Scholar
• Castillo K, Nassif M, Valenzuela V, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9(9):1308–1320.
   PubMed Web of Science ®Google Scholar
• Collibee SE, Bergnes G, Chuang C, et al. Discovery of reldesemtiv, a fast skeletal muscle troponin activator for the treatment of impaired muscle function. J Med Chem. 2021;64(20):14930–14941.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Andrews JA, Genge A, et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3–4):287–299.
   PubMed Web of Science ®Google Scholar
• Fels JA, Dash J, Leslie K, et al. Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts. Ann Clin Transl Neurol. 2022;9(10):1551–1564.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930.
   PubMed Web of Science ®Google Scholar
• Amylyx’s MA. ALS therapy secures FDA approval, as regulatory flexibility trumps underwhelming data. Nat Rev Drug Discov. 2022;21(11):786.
   Web of Science ®Google Scholar
• Zou S, Cannabinoid KU. Receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.
   PubMed Web of Science ®Google Scholar
• Raman C, McAllister SD, Rizvi G, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(1):33–39.
   PubMed Web of Science ®Google Scholar
• Moreno-Martet M, Espejo-Porras F, Fernandez-Ruiz J, et al. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex((R)) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20(9):809–815.
   PubMed Web of Science ®Google Scholar
• Urbi B, Broadley S, Bedlack R, et al. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. BMJ Open. 2019;9(11):e029449.
   PubMedGoogle Scholar
• Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11(10):1753–1763.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Nishimura Y, Shiide Y, et al. Evaluation of pharmacokinetics, safety, and drug-drug interactions of an oral suspension of edaravone in healthy adults. Clin Pharmacol Drug Dev. 2021;10(10):1174–1187.
   PubMed Web of Science ®Google Scholar
• Mora JS, Bradley WG, Chaverri D, et al. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211030365.
   Web of Science ®Google Scholar
• ALS NewsToday [Internet]. BioNews, Inc.; [cited 2022 Nov 20]. Available from: https://alsnewstoday.com/masitinib/
   Google Scholar
• Khalaf K, Tornese P, Cocco A, et al. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener. 2022;11(1):33.
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Sola S, Sharpe JC, et al. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry. 2003;42(10):3070–3080.
   PubMed Web of Science ®Google Scholar
• Elia AE, Lalli S, Monsurro MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45–52.
   PubMed Web of Science ®Google Scholar
• Albanese A, Ludolph AC, McDermott CJ, et al. Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: the TUDCA-ALS trial protocol. Front Neurol. 2022;13:1009113.
   PubMedGoogle Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099–1110.
   PubMed Web of Science ®Google Scholar
• Martinez A, Palomo Ruiz MD, Perez DI, et al. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2017;26(4):403–414.
   PubMed Web of Science ®Google Scholar
• Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104–118.
   PubMed Web of Science ®Google Scholar
• Mead RJ, Shan N, Reiser HJ, et al. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2022;1–28. DOI:10.1038/s41573-022-00612-2
   PubMed Web of Science ®Google Scholar
• Paganoni S, Berry JD, Quintana M, et al. Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development. Ann Neurol. 2022;91(2):165–175.
   PubMed Web of Science ®Google Scholar